MitoCell Secures Tens of Millions in Pre-A Funding to Accelerate Veterinary Stem Cell Therapeutics

VCBeat has learned that a leading domestic pet stem cell medical technology companyMitoCare (Shanghai) Biomedical Co., Ltd. (hereinafter referred to as “MitoCare”)Announced the completion ofTriwise CapitalLed a tens-of-millions-level Pre-A financing round. The funds will be primarily used forR&D of Pet Stem Cell Drugs and Clinical Translation of Technological Products,to consolidate the company’s technological leadership in the field of pet regenerative medicine.

In 2024, the total number of pet dogs and cats in China surpassed 187 million, with the pet population accelerating toward a 200-million-level market.^[1]Consequently, the issue of pet aging is becoming increasingly prominent. According to data from the "2023–2024 White Paper on China's Pet Industry," it is projected that over 30 million pets in China will enter middle and old age within the next three years.

As pets enter old age, the incidence of digestive diseases, metabolic disorders, cardiovascular and cerebrovascular diseases, endocrine disorders, and neurological diseases rises significantly. Against this backdrop,Stem cell medical technology brings new hope for anti-aging and chronic disease treatment in pets.

Stem cell therapy has demonstrated positive outcomes in the treatment of pet diseases such as osteoarthritis and atopic dermatitis, owing to its tissue repair and immunomodulatory functions. With continuous technological breakthroughs, stem cell therapy is poised to become a pivotal modality in veterinary medicine, not only enhancing the quality of life for geriatric pets but also extending their healthspan.

Meanwhile, as the pet healthcare consumption market continues to upgrade, there has been an explosive growth in pet owners’ demand for premium diagnostic and treatment services as well as personalized product experiences. Driven by the dual goals of extending pets’ lifespans and improving their quality of life, pet owners are increasingly inclined to choose more advanced treatment protocols to help their beloved companions maintain health and vitality during their senior years. This consumer trend resonates with technological innovations, opening up broad market prospects for the application and promotion of high-end medical technologies, such as stem cell therapy, in the veterinary field.

Mitouke, founded in 2022, specializes in the development of stem cell therapeutic drugs and medical technologies for geriatric pets, addressing a wide range of common conditions affecting the nervous, cardiovascular, musculoskeletal, and urinary systems. The company has been honored withNational High-Tech Enterprise, Zhongguancun High-Tech Enterprise, Beijing Technology-Based Small and Medium-sized Enterprise, and China’s Leading Quality Enterprise in the Pet Healthcare Industry, and simultaneously obtained triple certification for animal stem cell drugs under ISO 9001 (Quality Management System), ISO 14001 (Environmental Management System), and ISO 45001 (Occupational Health and Safety Management System).

Since its inception, Mitouke has focused onMesenchymal Stem Cell (MSC) Drugs, Medical Technologies, and Stem Cell-Derived Products for Petsdevelopment, while actively laying outHealth Management for Middle-Aged and Senior Petsand other fields, aiming to meet this growing market demand.

MiTouKe’s independently developed mesenchymal stem cell (MSC) glial culture system for pets significantly enhances stem cell viability, enabling cells from elderly pets to maintain exceptional regenerative capacity. Furthermore, its proprietary MSC cryopreservation and storage system successfully overcomes the technical challenge of viability loss during long-distance transportation of freshly thawed, viable MSCs. The synergistic application of these technologies efficiently preserves MSC viability from preparation to administration, thereby fundamentally ensuring the efficacy and safety of cell therapy.

Currently, Mi Tou Ke has already partnered withNew Ruipeng, Ruipai, Ruichen, Quanxin Quanyi, Yimeng, Chong'ai InternationalEstablish clinical research partnerships with multiple leading chain pet hospitals across China to jointly promote the clinical application of stem cell technology.

On January 8, 2025, Mitouke held a plaque-awarding ceremony with Quanxin Quanyi Animal Hospital

In the future, Mitouke will continue to deepen its expertise in pet stem cell medical technology, driving the pet healthcare industry toward a more precise and efficient era, and providing more breakthrough treatment solutions for pet health.

Regarding securing this round of financing,Dr. Ren Yu, Founder of Mitouke“The completion of this funding round not only signifies investors’ recognition of Mitouke’s technological prowess but also reflects strong confidence in the market prospects of pet stem cell therapy. With the accelerating trend of pet aging and the growing demand for chronic disease management, the clinical application of stem cell technology will become a key driver of market growth. Mitouke will continue to deepen its development of stem cell-based drugs and medical technologies, building a standardized and easily scalable cell therapy system to advance pet healthcare to higher levels. We thank Triwise Capital for its support and look forward to collaborating with more industry partners to jointly create a new future for pet healthcare.”

Triwise Pet Joy Fund Investment Team List“: The pet healthcare market is undergoing industrial upgrading, with stem cell technology emerging as a key direction for future precision medicine. Leveraging its outstanding technological innovation capabilities, Mitoque has established unique advantages in the fields of pet stem cell therapeutics and medical technology, demonstrating strong market expansion potential. We are highly optimistic about Mitoque’s future development in the field of veterinary regenerative medicine and believe that the company will accelerate technological breakthroughs to achieve industry leadership.”

Shenzhen Qianhai Triwise International Capital Management Co., Ltd. (P1030072), established in October 2015, is headquartered in Shenzhen with offices in Shanghai, Hangzhou, Changzhou, and Dongguan. Triwise Capital brings together seasoned industry professionals from Shenzhen Capital Group, Guosen Securities, Roche, GlaxoSmithKline (GSK), Bristol Myers Squibb (BMS), AbbVie, AstraZeneca, and BGI Genomics, as well as scientific experts from renowned academic institutions both domestically and internationally, focusing on investments in the healthcare and wellness sector.

Triwise Capital has obtained the qualification as one of the first batch of QFLP (Qualified Foreign Limited Partner) pilot management enterprises in Shenzhen Qianhai, and holds a stake in an SFC-licensed corporation holding Type 1, 4, and 9 licenses issued by the Hong Kong Securities and Futures Commission (SFC). To date, the company has initiated and established more than 30 RMB and USD funds, with assets under management totaling approximately RMB 4 billion.

References:

[1] Pet Fair Asia Research Institute, "2024 China Pet Industry Development Report"